U.S. Patent Disclosures
Galena Biopharma Inc., of Lake Oswego, Ore., received a notice of allowance for a composition-of-matter patent related to folate-binding peptide (FBP) variants, alone or combined with the FBP vaccine E39.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.